Global Vutrisiran Market Projected to Reach USD 2,087 Million by 2033 at a 12% CAGR

The global vutrisiran market, valued at USD 600 million in 2022, is expected to experience substantial growth, reaching an estimated USD 2,087 million by 2033, with a compound annual growth rate (CAGR) of 12% during the forecast period from 2023 to 2033.

This significant expansion can be attributed to the therapeutic promise of vutrisiran, which offers a fresh treatment option for individuals suffering from hereditary transthyretin-mediated amyloidosis (hATTR). As awareness of hATTR increases and more patients seek effective management strategies, the demand for vutrisiran is projected to rise.

In the historical period from 2018 to 2022, the vutrisiran market registered a CAGR of 5.1%, indicating a growing interest and uptake of this innovative therapy. The ongoing developments in treatment methodologies, combined with an increasing understanding of the condition, are expected to drive further market growth.

This upward trajectory highlights substantial opportunities for pharmaceutical companies and healthcare providers to improve patient outcomes and expand access to effective therapies for hATTR, ultimately enhancing the quality of life for those affected by this challenging condition.

2018 to 2022 Vutrisiran Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Vutrisiran reflected a value CAGR of 5.1% during the historical period, 2018 to 2022.

Vutrisiran received approval from the United States Food and Drug Administration (FDA) in September 2021 and approval from the European Medicines Agency (EMA) in November 2021. It is currently available in the United States, Europe, and other regions.

Based on the positive results of clinical trials and the approval by regulatory agencies, it is possible that the market for Vutrisiran may grow in the coming years. Thus, the market for vutrisiran is expected to register a CAGR of 12% in the forecast period 2023 to 2033.

Market Competition

Key players in the vutrisiran market are Alnylam Pharmaceuticals, Inc., Orphalan, AstraZeneca, Vivet Therapeutics, Pfizer, Ultragenyx Pharmaceutical, Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Merck & Co., Inc., Teva Pharmaceuticals

• Alnylam Pharmaceuticals invested significant time and resources into the research and development of Vutrisiran. The company conducted extensive clinical trials to demonstrate the safety and efficacy of the drug, which ultimately led to its approval by regulatory agencies.
• AstraZeneca and Alnylam have a strategic collaboration to co-develop and co-commercialize RNA interference (RNAi) therapeutics, including Vutrisiran. Under the agreement, Alnylam is responsible for the development and commercialization of certain RNAi therapeutics, including Vutrisiran, in the United States, Canada, and Western Europe, while AstraZeneca is responsible for development and commercialization in the rest of the world.

Key Companies Profiled

• Alnylam Pharmaceuticals, Inc.
• Orphalan
• AstraZeneca
• Vivet Therapeutics
• Pfizer Inc.
• Ultragenyx Pharmaceutical
• Valeant Pharmaceuticals International, Inc.
• Noblepharma Co., Ltd.
• Merck & Co., Inc.
• Teva Pharmaceuticals

A Full Report Overview

Key Segments Profiled in the Vutrisiran Industry Survey

Drug Class:

• Antisense Oligonucleotides
• Nucleic Acids
• Nucleotide
• Nucleosides

Route of Administration:

• Injectable
• Parenteral
• Subcutaneous

Distribution Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube